ArticleJCI insight2017
Efficacy of ALK5 inhibition in myelofibrosis.
Open access · goldAbstract read
In one paragraph
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 47 citations in OpenAlex.
- Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis.Nature communications · 2026Article
- Malignant JAK-signaling: at the interface of inflammation and malignant transformation.Leukemia · 2025Review
- Galunisertib attenuates pulmonary fibrosis with silicosis in mouse via TGF-β/TRAF6/Beclin1 signaling pathway.Frontiers in pharmacology · 2025Article
- Chronic Inflammation in Primary Myelofibrosis: In-Depth Insights Into Pathogenesis and Promising Anti-Inflammatory Therapeutic Strategies.Mediators of inflammation · 2025Review
- Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis.JCI insight · 2024Article
- Thioamides in medicinal chemistry and as small molecule therapeutic agents.European journal of medicinal chemistry · 2024Review
- SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.American journal of hematology · 2024Article
- SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.Blood cancer journal · 2023Article
- CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.Blood · 2023Article
- Novel therapeutics for myelofibrosis.Blood research · 2023Review
- Article
- TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.The Journal of clinical investigation · 2022Article
- Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models.Leukemia · 2022Article
- The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in theFrontiers in oncology · 2022Article
- The epigenetic regulator RINF (CXXC5) maintainsHaematologica · 2022Article
- Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.Frontiers in oncology · 2022Review
- A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms.Cancer discovery · 2021Article
- TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.JCI insight · 2021Article
- CDK6 Is a Therapeutic Target in Myelofibrosis.Cancer research · 2021Article
- JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.Journal of immunotherapy and precision oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 2 countries.
Lanzhu YueDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Matthias BartensteinDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Wanke ZhaoDepartment of Pathology, Peggy and Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA.
Wanting Tina HoDepartment of Pathology, Peggy and Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA.
Ying HanDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Cem MurdunDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Adam W MaillouxTranslational Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Ling ZhangDepartment of Hematopathology and Laboratory Medicine.
Xuefeng WangDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Anjali BudhathokiDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Kith PradhanDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Franck RapaportLeukemia Center, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Huaquan WangDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Zonghong ShaoDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Xiubao RenDepartment of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China.
Ulrich SteidlDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Ross L LevineLeukemia Center, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Zhizhuang Joe ZhaoDepartment of Pathology, Peggy and Stephenson Cancer Center, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA.
Amit VermaDepartment of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Pearlie K Epling-BurnetteDepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Albert Einstein College of Medicine · USMoffitt Cancer Center · USTianjin Medical University General Hospital · CNUniversity of Oklahoma Health Sciences Center · USMemorial Sloan Kettering Cancer Center · USTianjin Medical University Cancer Institute and Hospital · CN
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MMolecular Mechanisms of Immune Therapy for Bone Marrow FailureI01CX000114 · VA · JAMES A. HALEY VA MEDICAL CENTER · PI BURNETTE, PEARLIE K · 2009 to 2019
–CSRD VA I01 CX000114NCI NIH HHS P30 CA076292
Abstract
Myelofibrosis (MF) is a bone marrow disorder characterized by clonal myeloproliferation, aberrant cytokine production, extramedullary hematopoiesis, and bone marrow fibrosis. Although somatic mutations in
Indexed as
AnimalsBone MarrowCell DifferentiationCell ProliferationCells, CulturedCollagenHEK293 CellsHematopoietic Stem CellsHumansJanus Kinase 2MaleMegakaryocytesMesenchymal Stem CellsMiceMice, Inbred C57BLMice, TransgenicCollagenJak2 protein, mouseJanus Kinase 2LY-2157299Mpl protein, mousePyrazolesQuinolinesReceptors, ThrombopoietinReceptor, Transforming Growth Factor-beta Type ISmad3 ProteinTGFB1 protein, humanTgfb1 protein, mouseTgfbr1 protein, mouseTransforming Growth Factor beta1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.